Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
For the full year,net profit rose 34.07% to Rs 1442.41 crore in the year ended March 2026 as against Rs 1075.88 crore during the previous year ended March 2025. Sales rose 19.14% to Rs 8373.45 crore in the year ended March 2026 as against Rs 7028.46 crore during the previous year ended March 2025.
Suraksha Diagnostic Ltd lost 7.95% today to trade at Rs 294.5. The BSE Healthcare index is down 0.51% to quote at 47612.76. The index is up 9.48 % over last one month. Among the other constituents of the index, Max Healthcare Institute Ltd decreased 5.18% and Aurobindo Pharma Ltd lost 3.54% on the day. The BSE Healthcare index went up 11.99 % over last one year compared to the 7.03% fall in benchmark SENSEX.
Suraksha Diagnostic Ltd has added 4.27% over last one month compared to 9.48% gain in BSE Healthcare index and 4.15% drop in the SENSEX. On the BSE, 1019 shares were traded in the counter so far compared with average daily volumes of 3298 shares in the past one month. The stock hit a record high of Rs 353.65 on 26 Jun 2025. The stock hit a 52-week low of Rs 224.1 on 30 Mar 2026.
The company’s network gross revenue stood at Rs 2,664 crore, registering a 10% YoY growth, primarily driven by higher occupied bed days (OBDs). International patient revenue increased 12% YoY to Rs 227 crore and contributed around 9% of hospital revenue.
Network operating EBITDA came in at Rs 682 crore, up 8% YoY. EBITDA margin for the network stood at 26.8% compared with 27.2% in Q4 FY25 and 26.1% in Q3 FY26.
The company said clinician costs increased nearly 230 basis points YoY and 120 basis points sequentially due to aggressive hiring of clinical talent to support future growth and ongoing capacity expansions.
Overall EBITDA per bed stood at Rs 73.4 lakh compared with Rs 73.9 lakh in Q4 FY25 and Rs 71.3 lakh in Q3 FY26.
Max Lab, the company’s non-captive pathology business, reported revenue of Rs 52 crore during the quarter, reflecting growth of 14% YoY and 11% QoQ. The pathology network now operates across more than 60 cities and offers over 2,700 tests.
Max@Home reported gross revenue of Rs 73 crore, up 30% YoY and 8% QoQ, driven by growth in physiotherapy, rehabilitation, nursing care, sample collection, and medicine delivery services.
Network PAT stood at Rs 387 crore, compared with Rs 376 crore in Q4 FY25, registering growth of 3% YoY and 12% sequentially.
Free cash flow from operations rose to Rs 581 crore in Q4 FY26 from Rs 422 crore in the year-ago quarter. During the quarter, the company deployed Rs 328 crore towards ongoing expansion plans and new unit upgrades. Net debt at the end of March 2026 stood at Rs 1,908 crore compared with Rs 2,166 crore at the end of December 2025.
The company said nearly 20% additional brownfield capacity has been commissioned over the last six months, with another 10% capacity addition expected from the upcoming Gurugram facility later this year.
A 400-bed brownfield tower at Max Smart Super Speciality Hospital was commissioned in April 2026. Currently, 156 beds have been handed over to operations, with the remaining beds expected to be progressively handed over during the next quarter.
Additionally, a 160-bed brownfield tower at MSSH, Mohali has been fully commissioned and operationalized. Similarly, 116 beds out of the planned 280-bed brownfield tower at Nanavati Max have been operationalized, with the balance beds expected to become operational over the next three months.
Max Healthcare also completed the acquisition of a 58.28% controlling stake in Kalinga Hospital on 18 May 2026, making it a subsidiary of the company. Kalinga Hospital operates a 250-bed facility spread across a prime 10-acre land parcel in the heart of Bhubaneswar, Odisha.
Meanwhile, the board approved an investment of around Rs 1,400 crore for the construction of a 712-bed greenfield hospital at Shaheed Path in Lucknow. The facility is expected to be commissioned in FY30.
Abhay Soi, chairman and managing director, Max Healthcare Institute, said, “We are pleased to announce the phased commissioning and ramp-up of brownfield expansions across Mohali, Mumbai and Delhi, representing approximately 20% capacity addition. We also look forward to augmenting our capacity by another ~10% with the commissioning of the greenfield Gurgaon facility by the end of the year.
We are also happy that the network has delivered its 22nd consecutive quarter of year-on-year growth, with revenue increasing by 10% and operating EBITDA grew by 8%. Further, we have completed the acquisition of a controlling stake in Kalinga Hospital, Bhubaneswar. The team has already begun integration and is working towards achieving significant operational upside. In parallel, work has commenced on the upgradation and expansion of the hospital, enabling us to extend high-quality healthcare services in a fast-growing region.”
further, the company’s board has recommended a final dividend of Rs 2 per equity share of face value Rs 10 each for FY26, subject to shareholders’ approval at the forthcoming annual general meeting (AGM). If approved, the dividend will be paid or dispatched within 30 days from the conclusion of the AGM.
Max Healthcare Institute (Max Healthcare) is one of India’s largest healthcare organisations. The company operates 21 healthcare facilities (nearly 6,000 beds) with a significant presence in North India. In addition to the hospitals, Max Healthcare operates homecare and pathology businesses under brand names Max@Home and Max Lab, respectively.
The scrip had added 1.42% to end at Rs 1091.55 on the BSE.
Further, the board has approved to provide loans up to Rs 100 crore to KHL towards cost of construction, renovation, upgradation, equipment etc. The Board has also approved issuance of corporate guarantee to Bank/ Financial Institution for re-financing of external commercial borrowings of existing promoter of KHL of $5 Mn (along with interest due thereon).
Also, the board has approved the senior secured term loan of amount up to Rs 300 crore in the form of external commercial borrowings for financing the acquisition.
Under the agreement, MHIL shall acquire 58.4% stake in KHL at an equity value of Rs 300 crore.
The 250 bed NABH accredited hospital is built on a 10-acre land parcel at Maitri Vihar, Bhubaneswar, a prime location in the heart of the city. Spread over 2.60 lakh square feet, the hospital provides multidisciplinary care across major specialties, including neurology, cardiology, orthopaedics, gastroenterology, renal sciences and oncology; backed by diagnostics and equipped with a 128-slice CT scanner, 1.5T MRI, and cath lab, etc.
Bhubaneswar has a well-developed healthcare eco-system with large footprint of public, private hospitals and multiple medical colleges, positioning the city as a preferred healthcare provider for patients from across Odisha and neighbouring states of West Bengal, Jharkhand and Chhattisgarh.
This acquisition will strengthen MHIL’s network and expand its footprint in Eastern India.
Abhay Soi, chairman and managing director, Max Healthcare Institute, said: “Happy to announce our foray into Bhubaneswar, an extremely attractive market, through the acquisition of a very well located and reputable hospital with significant operational upside and brownfield potential.”
Max Healthcare Institute is one of India’s largest healthcare organizations. The company operates 20 healthcare facilities, with a significant presence in North India. In addition to the hospitals, Max Healthcare operates homecare and pathology businesses under brand names Max@Home and Max Lab, respectively.
The company's consolidated net profit rose 26.01% to Rs 300.92 crore on a 10.66% increase in revenue to Rs 2,067.52 crore in Q3 FY26 over Q3 FY25.